In early look at ASH abstracts, BeiGene touts Brukinsa data, Cellectis compares in-house CAR-T to CDMO CAR-T

The non-late breaking abstracts for next month’s American Society of Hematology meeting were released on Thursday, giving a peek into what will be some of the most heavily scrutinized data in San Diego in early December.

Below are a handful of the most notable:

Brukinsa still outperforming Imbruvica in CLL:…
Click here to view original post